Clinical Trials Logo

Tuberculosis, MDR clinical trials

View clinical trials related to Tuberculosis, MDR.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06441006 Not yet recruiting - Clinical trials for Tuberculosis, Pulmonary

Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis

PRISM-TB
Start date: November 1, 2024
Phase: Phase 3
Study type: Interventional

PRISM-TB is an international, multicenter, open-label, randomized, controlled, pragmatic, stratified medicine, treatment shortening, noninferiority Phase 3 clinical trial for fluoroquinolone-susceptible multidrug-resistant/rifampin-resistant pulmonary tuberculosis (FQ-S MDR/RR-TB). The trial objective is to evaluate whether stratified medicine treatment strategies for FQ-S MDR/RR-TB, defined by a pre-specified risk stratification algorithm, have noninferior efficacy to a one-size-fits-all control regimen (the local standard-of-care [SOC] regimen consistent with preferred regimen(s) in international guidelines), as measured by TB-related unfavorable outcomes at Week 73.